重组新型冠状病毒疫苗(腺病毒5型载体)单剂接种在18岁及以上成人中的最终效力分析、中期安全性分析和免疫原性:一项国际多中心随机双盲安慰剂对照3期试验
该国际多中心随机双盲安慰剂对照3期试验评估单剂Ad5-nCoV疫苗在18岁及以上成人中的效力与安全性。结果显示,接种后28天及以上对有症状、PCR确诊COVID-19的效力为57.5%(95%CI 39.7-70.0,p=0.0026),严重不良事件发生率与安慰剂组无显著差异。
要点
- 单剂Ad5-nCoV对接种28天及以上有症状、PCR确诊COVID-19的效力为57.5%(95%CI 39.7-70.0)。
- 严重不良事件发生率Ad5-nCoV组0.1%与安慰剂组0.1%无显著差异(p=0.54)。
- 扩展安全性队列中,Ad5-nCoV组 solicited 全身不良事件发生率63.5%,高于安慰剂组的46.4%(p<0.0001)。
核心结论
- 单剂Ad5-nCoV在18岁及以上健康成人中有效且安全。
研究设计与样本
- 国际多中心、随机、双盲、安慰剂对照、终点事件驱动的3期临床试验,在阿根廷、智利、墨西哥、巴基斯坦和俄罗斯的研究中心入组18岁及以上成人。
- 参与者按1:1随机接受单次肌内注射0.5 mL安慰剂或0.5 mL 5×10^10病毒颗粒(vp)/mL的Ad5-nCoV疫苗。
- 主要效力目标评估所有在2021年1月15日接种后至少28天的参与者中,接种后至少28天发生有症状、PCR确诊COVID-19的预防效果。
- 主要安全目标评估所有接受研究注射的参与者中接种后任何严重不良事件或需医疗关注的不良事件发生率。
主要发现
- 单剂Ad5-nCoV对接种后28天及以上有症状、PCR确诊COVID-19的效力为57.5%(95%CI 39.7-70.0,p=0.0026)(21250名参与者;中位随访45天[IQR 36-58])。
- 严重不良事件发生率:Ad5-nCoV组18363例中14例(0.1%) vs 安慰剂组18354例中10例(0.1%),p=0.54,无显著差异。
- 需医疗关注的不良事件发生率:Ad5-nCoV组18363例中442例(2.4%) vs 安慰剂组18354例中411例(2.2%),p=0.30,无显著差异。
- 两组均未报告被认为与研究产品相关的严重不良事件。
- 扩展安全性队列中,Ad5-nCoV组1582例中1004例(63.5%) vs 安慰剂组1572例中729例(46.4%)报告征集性全身不良事件(p<0.0001),头痛最常见(Ad5-nCoV组699例[44%] vs 安慰剂组481例[30.6%],p<0.0001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Ad5-nCoV vaccine is a single-dose adenovirus type 5 (Ad5) vectored vaccine expressing the SARS-CoV-2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies. In this study, we report results on the final efficacy and interim safety analyses of the phase 3 trial. METHODS: This double-blind, randomised, international, placebo-controlled, endpoint-case driven, phase 3, clinical trial enrolled adults aged 18 years older at study centres in Argentina, Chile, Mexico, Pakistan, and Russia. Participants were eligible for the study if they had no unstable or severe underlying medical or psychiatric conditions; had no history of a laboratory-confirmed SARS-CoV-2 infection; were not pregnant or breastfeeding; and had no previous receipt of an adenovirus-vectored, coronavirus, or SARS-CoV-2 vaccine. After informed consent was obtained, 25 mL of whole blood was withdrawn from all eligible participants who were randomised in a 1:1 ratio to receive a single intramuscular dose of 0·5 mL placebo or a 0·5 mL dose of 5 × 1010 viral particle (vp)/mL Ad5-nCoV vaccine; study staff and participants were blinded to treatment allocation. All participants were contacted weekly by email, telephone, or text message to self-report any symptoms of COVID-19 illness, and laboratory testing for SARS-CoV-2 was done for all participants with any symptoms. The primary efficacy objective evaluated Ad5-nCoV in preventing symptomatic, PCR-confirmed COVID-19 infection occurring at least 28 days after vaccination in all participants who were at least 28 days postvaccination on Jan 15, 2021. The primary safety objective evaluated the incidence of any serious adverse events or medically attended adverse events postvaccination in all participants who received a study injection. This trial is closed for enrolment and is registered with ClinicalTrials.gov (NCT04526990). FINDINGS: Study enrolment began on Sept 22, 2020, in Pakistan, Nov 6, 2020, in Mexico, Dec 2, 2020, in Russia and Chile, and Dec 17, 2020, in Argentina; 150 endpoint cases were reached on Jan 15, 2021, triggering the final primary efficacy analysis. One dose of Ad5-nCoV showed a 57·5% (95% CI 39·7-70·0, p=0·0026) efficacy against symptomatic, PCR-confirmed, COVID-19 infection at 28 days or more postvaccination (21 250 participants; 45 days median duration of follow-up [IQR 36-58]). In the primary safety analysis undertaken at the time of the efficacy analysis (36 717 participants), there was no significant difference in the incidence of serious adverse events (14 [0·1%] of 18 363 Ad5-nCoV recipients and 10 [0·1%] of 18 354 placebo recipients, p=0·54) or medically attended adverse events (442 [2·4%] of 18 363 Ad5-nCoV recipients and 411 [2·2%] of 18 354 placebo recipients, p=0·30) between the Ad5-nCoV or placebo groups, or any serious adverse events considered related to the study product (none in both Ad5-nCoV and placebo recipients). In the extended safety cohort, 1004 (63·5%) of 1582 of Ad5-nCoV recipients and 729 (46·4%) of 1572 placebo recipients reported a solicited systemic adverse event (p<0·0001), of which headache was the most common (699 [44%] of Ad5-nCoV recipients and 481 [30·6%] of placebo recipients; p<0·0001). 971 (61·3%) of 1584 Ad5-nCoV recipients and 314 (20·0%) of 1573 placebo recipients reported an injection-site adverse event (p<0·0001), of which pain at the injection site was the most frequent; reported by 939 (59%) Ad5-nCoV recipients and 303 (19%) placebo recipients. INTERPRETATION: One dose of Ad5-nCoV is efficacious and safe in healthy adults aged 18 years and older. FUNDING: CanSino Biologics and the Beijing Institute of Biotechnology.
引用
- Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2021. PMID: 34953526. doi:10.1016/S0140-6736(21)02753-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。